Publications

This web page presents, in inverse chronological order, all published science papers of Dr. Charmandari.

Refereed Papers

    2017 - [7]

  1. Bacopoulou F, Kolias E, Efthymiou V, Antonopoulos CN, Charmandari E. Vitamin D predictors in polycystic ovary syndrome: A meta-analysis. Eur J Clin Invest. 2017 Aug 10. doi: 10.1111/eci.12800. [Epub ahead of print]
  2. Nicolaides NC, Kino T, Roberts ML, Katsantoni E, Sertedaki A, Moutsatsou P, Psarra AG, Chrousos GP, Charmandari E. The Role of S-Palmitoylation of the Human Glucocorticoid Receptor (hGR) in Mediating the Nongenomic Glucocorticoid Actions. J Mol Biochem. 2017;6(1):3-12. Epub 2017 Apr 15.
  3. Nicolaides NC, Charmandari E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. Hormones (Athens). 2017 Apr;16(2):124-138. doi: 10.14310/horm.2002.1728. Review.
  4. Nicolaides NC, Charmandari E., Kino T, Chrousos GP. Stress-Related and Circadian Secretion and Target Tissue Actions of Glucocorticoids: Impact on Health. Front Endocrinol (Lausanne). 2017 Apr 28;8:70. doi: 10.3389/fendo.2017.00070. eCollection 2017. Review.
  5. Kyritsi EM, Koltsida G, Farakla I, Papanikolaou A, Critselis E, Mantzou E, Zoumakis E, Kolaitis G, Chrousos GP, Charmandari E. Psychological vulnerability to stress in carriers of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormones (Athens). 2017 Jan;16(1):42-53. doi: 10.14310/horm.2002.1718.
  6. Vardas K, Ilia S, Sertedaki A, Charmandari E., Briassouli E, Goukos D, Apostolou K, Psarra K, Botoula E, Tsagarakis S, Magira E, Routsi C, Stratakis CA, Nanas S, Briassoulis G. Increased glucocorticoid receptor expression in sepsis is related to heat shock proteins, cytokines, and cortisol and is associated with increased mortality. Intensive Care Med Exp. 2017 Dec;5(1):10. doi: 10.1186/s40635-017-0123-8.
  7. Stavrou S, Nicolaides NC, Critselis E, Darviri C, Charmandari E., Chrousos GP. Pediatric Stress: From Neuroendocrinology to Contemporary Disorders. Eur J Clin Invest. 2017 Mar;47(3):262-269. doi: 10.1111/eci.12724. Review.

    2016 - [8]

  8. Sertedaki A, Markou A, Vlachakis D, Kossida S, Campanac E, Hoffman DA, Sierra ML, Xekouki P, Stratakis CA, Kaltsas G, Piaditis GP, Chrousos GP, Charmandari E. Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion. Clin Endocrinol (Oxf). 2016 Dec;85(6):845-851. doi: 10.1111/cen.13132.
  9. Kassi E, Semaniakou A, Sertedaki A, Evangelopoulos ME, Kazazoglou T, Kominakis A, Sfagos C, Charmandari E, Chrousos GP, Moutsatsou P. Sequencing analysis of the human glucocorticoid receptor (NR3C1) gene in multiple sclerosis patients. J Neurol Sci. 2016 Apr 15;363:165-9. doi: 10.1016/j.jns.2016.02.054. Epub 2016 Feb 23.
  10. Hurt DE, Suzuki S, Mayama T, Charmandari E, Kino T. Structural Analysis on the Pathologic Mutant Glucocorticoid Receptor Ligand-binding Domains. Mol Endocrinol. 2016 Feb;30(2):173-88. doi: 10.1210/me.2015-1177. Epub 2016 Jan 8.
  11. Nicolaides NC, Skyrla E, Vlachakis D, Psarra AM, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E. Functional characterization of the hGRαT556I causing Chrousos syndrome. Eur J Clin Invest. 2016 Jan;46(1):42-9. doi: 10.1111/eci.12563.
  12. Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, Baratz Dalke K, Liao LM, Lin-Su K, Looijenga LH 3rd, Mazur T, Meyer-Bahlburg HF, Mouriquand P, Quigley CA, Sandberg DE, Vilain E, Witchel S; Global DSD Update Consortium. Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. Horm Res Paediatr. 2016;85(3):158-80. doi: 10.1159/000442975. Epub 2016 Jan 28.
  13. Nicolaides N, Lamprokostopoulou A, Sertedaki A, Charmandari E. Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. Hormones (Athens). 2016 Jan;15(1):23-34. doi: 10.14310/horm.2002.1660. Review.
  14. Stavrou S, Nicolaides NC, Papageorgiou I, Papadopoulou P, Terzioglou E, Chrousos GP, Darviri C, Charmandari E. The effectiveness of a stress-management intervention program in the management of overweight and obesity in childhood and adolescence. J Mol Biochem. 2016;5(2):63-70.
  15. Charmandari E., Guan R, Zhang M, Silveira LG, Fan QR, Chrousos GP, Sertedaki AC, Latronico AC, Segaloff DL. Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation. Mol Endocrinol. 2016 Jan;30(1):62-76. doi: 10.1210/me.2015-1205.

    2015 - [6]

  16. Nicolaides NC, Lamprokostopoulou A, Polyzos A, Kino T, Katsantoni E, Triantafyllou P, Christophoridis A, Katzos G, Dracopoulou M, Sertedaki A, Chrousos GP, Charmandari E. Transient Generalized Glucocorticoid Hypersensitivity. Eur J Clin Invest. 2015 Dec;45(12):1306-15. doi: 10.1111/eci.12554. Epub 2015 Nov 20.
  17. Nicolaides NC, Geer EB, Vlachakis D, Roberts ML, Psarra AM, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E. A novel mutation of the hGR gene causing Chrousos syndrome. Eur J Clin Invest. 2015 Aug;45(8):782-91. doi: 10.1111/eci.12470. Epub 2015 Jul 14.
  18. Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, Gouli A, Papanastasiou L, Fountoulakis S, Zacharoulis A, Karavidas A, Ragkou D, Charmandari E, Chrousos GP, Piaditis GP. Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension. J Clin Endocrinol Metab. 2015 Aug;100(8):2857-64. doi: 10.1210/jc.2015-1268. Epub 2015 May 14.
  19. Nicolaides NC, Charmandari E Chrousos Syndrome: From Molecular Pathogenesis to Therapeutic Management. Eur J Clin Invest. 2015 May;45(5):504-14. doi: 10.1111/eci.12426. Epub 2015 Mar 23
  20. Hindmarsh PC, Charmandari E Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. Clin Endocrinol (Oxf). 2015 Apr;82(4):557-61. doi: 10.1111/cen.12653.
  21. Nicolaides NC, Kyratzi E, Lamprokostopoulou A, Chrousos GP, Charmandari E Stress, the stress system and the role of glucocorticoids. Neuroimmunomodulation. 2015;22(1-2):6-19. doi: 10.1159/000362736. Epub 2014 Sep 12.

    2014 - [7]

  22. Nicolaides NC, Charmandari E, Chrousos GP., Kino T. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor. BMC Endocr Disord. 2014 Aug 25;14:71. doi: 10.1186/1472-6823-14-71.
  23. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal Insufficiency. Lancet. 2014 Feb 3. pii: S0140-6736(13)61684-0. doi: 10.1016/S0140-6736(13)61684-0.
  24. Nicolaides NC, Charmandari E, Chrousos GP., Kino T. Circadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actions.. Ann N Y Acad Sci. 2014 May;1318:71-80. doi: 10.1111/nyas.12464.
  25. Nicolaides NC, Roberts ML, Kino T, Braatvedt G, Hurt DE, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.. J Clin Endocrinol Metab. 2014 May;99(5):E902-7. doi: 10.1210/jc.2013-3005.
  26. Moschonis G, Kalliora AC, Costarelli V, Papandreou C, Koutoukidis D, Lionis C, Chrousos GP, Manios Y; Healthy Growth Study Group.. (Charmandari E). Identification of lifestyle patterns associated with obesity and fat mass in children: the Healthy Growth Study.. Public Health Nutr. 2014 Mar;17(3):614-24. doi: 10.1017/S1368980013000323.
  27. Manios Y, Moschonis G, Papandreou C, Siatitsa PE, Iatridi V, Lidoriki I, Lionis C, Chrousos GP; Healthy Growth Study group. (Charmandari E). Female sex, small size at birth and low family income increase the likelihood of insulin resistance in late childhood: the Healthy Growth Study.. Pediatr Diabetes. 2014 Feb;15(1):41-50. doi: 10.1111/pedi.12052.
  28. Androutsos O, Moschonis G, Koumpitski A, Mantzou A, Roma-Giannikou E, Chrousos GP, Manios Y, Kanaka-Gantenbein C; “Healthy Growth Study” Group. (Charmandari E). The correlation of right 2D:4D finger length ratio to the low-grade inflammation marker IL-6 in children. The Healthy Growth Study.. Early Hum Dev. 2014 Jan;90(1):61-5. doi: 10.1016/j.earlhumdev.2013.10.003.

    2013 - [5]

  29. Manios Y, Birbilis M, Moschonis G, Birbilis G, Mougios V, Lionis C, Chrousos GP; “Healthy Growth Study” group (Charmandari E). Childhood Obesity Risk Evaluation based on perinatal factors and family sociodemographic characteristics: CORE index. Eur J Pediatr. 2013; 172(4): 551-5.
  30. Roberts ML, Kino T, Nicolaides NC, Hurt DE, Katsantoni E, Sertedaki A, Komianou F, Kassiou K, Chrousos GP, Charmandari E. A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD. J Clin Endocrinol Metab. 2013; 98(4): E790-5.
  31. Peters CJ, Hill N, Dattani MT, Charmandari E, Matthews DR, Hindmarsh PC. Deconvolution analysis of 24-h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 2013; 78(3): 347-51.
  32. Charmandari E, Kino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013; 24:67-85.
  33. Birbilis M, Moschonis G, Mougios V, Manios Y; Healthy Growth Study’ group (Charmandari E). Obesity in adolescence is associated with perinatal risk factors, parental BMI and sociodemographic characteristics. Eur J Clin Nutr. 2013; 67(1): 115-21.

    2012 - [4]

  34. Charmandari E, Achermann JC, Carel JC, Soder O, Chrousos GP. Stress response and child health. Sci Signal. 2012; 5(248): mr1.
  35. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity: the end-organ involvement in the stress response. Sci Signal. 2012; 5(244): pt5.
  36. Moschonis G, Chrousos GP, Lionis C, Mougios V, Manios Y; Healthy Growth Study group (Charmandari E). Association of total body and visceral fat mass with iron deficiency in preadolescents: the Healthy Growth Study. Br J Nutr. 2012; 108(4): 710-9.
  37. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012; 97(8): E1532-9.

    2011 - [4]

  38. Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Manios Y, Bartzeliotou A, Chrousos GP, Charmandari E. Plasma proteomic analysis in obese and overweight prepubertal children. Eur J Clin Invest. 2011; 41(12): 1275-83.
  39. Kino T, Charmandari E, Chrousos GP. Glucocorticoid receptor: implications for rheumatic diseases. Clin Exp Rheumatol. 2011; 29(5 Suppl 68): S32-41.
  40. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity. Horm Res Paediatr. 2011; 76(3): 145-55.
  41. Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SS, Kino T. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011; 6(9): e25612.

    2010 - [2]

  42. Charmandari E, Kino T. Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes. Eur J Clin Invest. 2010; 40(10): 932-42.
  43. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010; 75(1): 1-12.

    2009 - [2]

  44. Charmandari E, Chrousos GP, Kino T. Identification of natural human glucocorticoid receptor (hGR) mutations or polymorphisms and their functional consequences at the hormone-receptor interaction level. Methods Mol Biol. 2009; 590:33-60.
  45. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. Neuroimmunomodulation. 2009; 16(5): 272-83.

    2008 - [2]

  46. Charmandari E, Ichijo T, Jubiz W, Baid S, Zachman K, Chrousos GP, Kino T. A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. J Clin Endocrinol Metab. 2008; 93(12): 4963-8.
  47. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab. 2008; 93(5): 1563-72.

    2007 - [3]

  48. Charmandari E, Kino T, Ichijo T, Jubiz W, Mejia L, Zachman K, Chrousos GP. A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. J Clin Endocrinol Metab. 2007; 92(10): 3986-90.
  49. Charmandari E, Kino T. Novel causes of generalized glucocorticoid resistance. Horm Metab Res. 2007; 39(6): 445-50.
  50. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res. 2007; 22(1): 110-8.

    2006 - [3]

  51. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann N Y Acad Sci. 2006; 1083:37-53.
  52. Kino T, Souvatzoglou E, Charmandari E, Ichijo T, Driggers P, Mayers C, Alatsatianos A, Manoli I, Westphal H, Chrousos GP, Segars JH. Rho family Guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system. J Biol Chem. 2006; 281(14): 9118-26.
  53. Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance. J Clin Endocrinol Metab. 2006; 91(4): 1535-43.

    2005 - [5]

  54. Charmandari E, Raji A, Kino T, Ichijo T, Tiulpakov A, Zachman K, Chrousos GP. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity. J Clin Endocrinol Metab. 2005; 90(6): 3696-705.
  55. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005; 67:259-84.
  56. Kino T, De Martino MU, Charmandari E, Ichijo T, Outas T, Chrousos GP. HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes. 2005; 54(1): 23-31.
  57. Charmandari E, Chrousos GP, Merke DP. Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab. 2005; 18(1): 97-101.
  58. Charmandari E, Chrousos GP, Ichijo T, Bhattacharyya N, Vottero A, Souvatzoglou E, Kino T. The human glucocorticoid receptor (hGR) beta isoform suppresses the transcriptional activity of hGRalpha by interfering with formation of active coactivator complexes. Mol Endocrinol. 2005; 19(1): 52-64.

    2004 - [9]

  59. Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol. 2004; 151 Suppl 3: U77-82.
  60. Weise M, Drinkard B, Mehlinger SL, Holzer SM, Eisenhofer G, Charmandari E, Chrousos GP, Merke DP. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab. 2004; 89(8): 3679-84.
  61. Kino T, Liou SH, Charmandari E, Chrousos GP. Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function. Mol Med. 2004; 10(7-12): 80-8.
  62. Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci. 2004; 1024: 168-81.
  63. Charmandari E, Kino T, Chrousos GP. Glucocorticoids and their actions: an introduction. Ann N Y Acad Sci. 2004; 1024: 1-8.
  64. Charmandari E, Merke DP, Negro PJ, Keil MF, Martinez PE, Haim A, Gold PW, Chrousos GP. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab. 2004; 89(5): 2228-36.
  65. Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP. Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab. 2004; 89(4): 1939-49.
  66. Weise M, Mehlinger SL, Drinkard B, Rawson E, Charmandari E, Hiroi M, Eisenhofer G, Yanovski JA, Chrousos GP, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise. J Clin Endocrinol Metab. 2004; 89(2): 591-7.
  67. Chrousos GP, Charmandari E, Kino T. Glucocorticoid action networks--an introduction to systems biology. J Clin Endocrinol Metab. 2004; 89(2): 563-4.

    2003 - [6]

  68. Kino T, Charmandari E, Chrousos GP. Basic and clinical implications of glucocorticoid action--focus on development. National Institutes of Health, Bethesda, Maryland, USA. June 17-18, 2003. Introduction and abstracts. Horm Metab Res. 2003; 35(10): 628-48.
  69. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Sexual dimorphism in the synchrony of joint growth hormone and cortisol dynamics in children with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab. 2003; 16(8): 1119-30.
  70. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol. 2003; 85(2-5): 457-67.
  71. Roche EF, Charmandari E, Dattani MT, Hindmarsh PC. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf). 2003; 58(5): 589-96.
  72. Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol. 2003; 40(4): 224-9.
  73. Charmandari E, Kino T, Souvatzoglou E, Chrousos GP. Pediatric stress: hormonal mediators and human development. Horm Res. 2003; 59(4): 161-79.

    2002 - [7]

  74. Kino T, Vottero A, Charmandari E, Chrousos GP. Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann N Y Acad Sci. 2002; 970: 101-11.
  75. Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2002; 87(7): 3197-200.
  76. Charmandari E, Eisenhofer G, Mehlinger SL, Carlson A, Wesley R, Keil MF, Chrousos GP, New MI, Merke DP. Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2002; 87(7): 3031-7.
  77. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion. J Clin Endocrinol Metab. 2002; 87(5): 2238-44.
  78. Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab. 2002; 87(5): 2114-20.
  79. Charmandari E, Brook CG, Hindmarsh PC. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch Dis Child. 2002; 86(4): 266-9.
  80. Charmandari E, Johnston A, Honour JW, Brook CG, Hindmarsh PC. Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2002; 15(4): 435-9.

    2001- - [10]

  81. Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory? J Clin Endocrinol Metab. 2001; 86(10): 4679-85.
  82. Charmandari E, Lichtarowicz-Krynska EJ, Hindmarsh PC, Johnston A, Aynsley-Green A, Brook CG. Congenital adrenal hyperplasia: management during critical illness. Arch Dis Child. 2001; 85(1): 26-8.
  83. Charmandari E, Pincus SM, Matthews DR, Dennison E, Fall CH, Hindmarsh PC. Joint growth hormone and cortisol spontaneous secretion is more asynchronous in older females than in their male counterparts. J Clin Endocrinol Metab. 2001; 86(7): 3393-9.
  84. Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001; 86(6): 2701-8.
  85. Charmandari E, Johnston A, Brook CG, Hindmarsh PC. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol. 2001; 169(1): 65-70.
  86. Charmandari E, Meadows N, Patel M, Johnston A, Benjamin N. Plasma nitrate concentrations in children with infectious and noninfectious diarrhea. J Pediatr Gastroenterol Nutr. 2001; 32(4): 423-7.
  87. Charmandari E. Is hydrocortisone clearance 50% slower in the evening than in the morning? J Clin Endocrinol Metab. 2001; 86(2): 948-9.
  88. Charmandari E, Dattani MT, Perry LA, Hindmarsh PC, Brook CG. Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res. 2001; 56(5-6): 177-81.
  89. Koziell A, Charmandari E, Hindmarsh PC, Rees L, Scambler P, Brook CG. Frasier syndrome, part of the Denys Drash continuum or simply a WT1 gene associated disorder of intersex and nephropathy? Clin Endocrinol (Oxf). 2000; 52(4): 519-24.
  90. Charmandari E, Brook CG. 20 years of experience in idiopathic central diabetes insipidus. Lancet. 1999; 353(9171): 2212-3.

Chapters in Books

  1. Van den Akker ELT, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, Ken Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2013; Pages: 97-111.
  2. Pervanidou P, Charmandari E, Chrousos GP. Endocrine aspects of childhood obesity. Current Pediatric Reports, Ronald Kleinman (Editor), Springer Science & Business Media, New York, NY, USA; 2012 (in press).
  3. Charmandari E, Chrousos GP. The Effect of Stress on the Hypothalamic-pituitary-adrenal Axis: An Update. In Neuroendocrine Disorders in Children, Mehul T. Dattani (Editor), McKeith Press, London, UK; 2012 (in press).
  4. Charmandari E, Chrousos GP. Primary Generalized Glucocorticoid Resistance or Chrousos syndrome. In Oxford Desk Reference - Endocrinology, Helen Turner, Ashley Grossman and Richard Eastell (eds), Oxford University Press, Oxford, UK; 2012 (in press).
  5. Charmandari E, Kino T, Chrousos GP. Primary Generalized Familial and Sporadic Glucocorticoid Resistance (Chrousos syndrome) and Hypersensitivity. In Endocrine Development, Maghnie M (ed); 2012 (in press).
  6. Van den Akker ELT, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, Ken Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2012; Pages: 99-115.
  7. Charmandari E, Kino T, Chrousos GP. Primary Generalized Glucocorticoid Resistance and Hypersensitivity. In Endocrine Hypertension, Koch CA, Chrousos GP (eds), Springer, Humana Press, USA; 2011 (in press).
  8. Van den Akker ELT, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, JC Carel, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2011; Pages 99-119.
  9. Charmandari E. Delayed puberty. In Primary medical care for children and adolescents. Chrysanthopoulos C (eds) 2011; (in press).
  10. Charmandari E. Precocious puberty. In Primary medical care for children and adolescents. Chrysanthopoulos C (eds) 2011; (in press).
  11. Kino T, Charmandari E, Chrousos GP. Disorders of the hypothalamic-pituitary- adrenocortical system. In Handbook of Neuroendocrinology. George Fink, Donald Pfaff and Jon Levine (eds), Elsevier, San Diego, California, USA, 2011 (in press).
  12. Van den Akker ELT, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, JC Carel, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2010; Pages 99-118.
  13. Charmandari E, Kino T, Chrousos GP. Glucocorticoids. In Neonatal and Pediatric Pharmacology, 4th Edition. Yaffe SJ and Aranda JV (eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2010; Chapter 51, pages: 760-772.
  14. Charmandari E, Chrousos GP, Kino T. Identification of Natural Human Glucocorticoid Receptor (hGR) Mutations or Polymorphisms and their Functional Consequences at the Hormone-Receptor Interaction Level. In Methods in Molecular Biology - Molecular Endocrinology: A Comprehensive Guide to Current Methodologies. Sarge OP and Curry T (eds), Humana Press, USA, 2009; Chapter 3, pages 33-60.
  15. Charmandari E. Puberty and Adrenarche. In Reproductive Endocrinology. Mastorakos G (eds) 2008; Chapter 21 (in press).
  16. Charmandari E, Kino T, Chrousos GP. Generalized Glucocorticoid Insensitivity: Clinical Phenotype and Molecular Mechanisms. In Overcoming Steroid Insensitivity in Respiratory Disease. Adcock I and Chung F (eds), John Wiley & Sons, Ltd, United Kingdom, 2008; Chapter 5, pages 73-87.
  17. Charmandari E, Chrousos GP, Merke DP. Classic Congenital Adrenal Hyperplasia. In Adrenal Glands: Diagnostic Aspects and Surgical Therapy. Linos DA and van Heerden JA (eds) Springer-Verlag, Germany, 2005; Chapter 10, pages 101-114.
  18. Kino T, Charmandari E, Chrousos GP. Glucocorticoid action - Basic and clinical implications. Annals of the New York Academy of Sciences 2004; Volume 1024; pages 1-221.
  19. Charmandari E, Kino T, Chrousos GP. Glucocorticoids. In Neonatal and Pediatric Pharmacology, 3rd Edition. Yaffe SJ and Aranda JV (eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2004; pages 713-726.
  20. Charmandari E, Chrousos GP. Glucocorticoids, Overview. In Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 253-259.
  21. Charmandari E, Kino T, Chrousos GP. Glucocorticoid Receptor. In Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 229-234.
  22. Charmandari E, Chrousos GP. Adrenal Insufficiency. In Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 75-80.

Online Journals

  1. Charmandari E, Kino T, Chrousos GP. Primary Generalized Glucocorticoid Resistance syndrome. In Pediatric Medicine, Endocrinology. Neish SR (ed). 2012
  2. Karaflou M, Charmandari E, Sertedaki A, Chrousos GP. Familial or sporadic adrenal hypoplasia syndromes. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2012
  3. Nicolaides N, Charmandari E, Chrousos GP. Adrenal insufficiency. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2012
  4. Charmandari E, Kino T, Chrousos GP. Glucocorticoid resistance syndrome. In Pediatric Medicine, Endocrinology. Neish SR (ed). 2010
  5. Kino T, Charmandari E, Vottero A. Glucocorticoid Resistance Syndromes and States. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2010
  6. Kino T, Charmandari E, Chrousos GP. Glucocorticoid Receptor. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2010
  7. Charmandari E, Kino T, Chrousos GP. Molecular mechanisms of glucocorticoid action. In Orpha.net 2004
  8. Charmandari E, Kino T, Chrousos GP. Familial/Sporadic glucocorticoid resistance. In Orpha.net 2004
  9. Charmandari E, Kino T, Chrousos GP. Glucocorticoid resistance syndrome. In Pediatric Medicine, Endocrinology. Neish SR (ed). 2003
  10. Charmandari E, Chrousos GP. Adrenal insufficiency. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 13
  11. Kino T, Charmandari E, Chrousos GP. Glucocorticoid Receptor. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 6
  12. Kino T, Charmandari E, Chrousos GP. Glucocorticoids: synthesis, action, physiology. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 2